Home Compare GSK.L vs ORNBV.HE
Stock Comparison · Industry comparison · Drug Manufacturers - General

GSK vs Orion Oyj: Which Stock Looks Stronger in 2026?

Orion Oyj holds the cleaner structural position, with the lead spread across profitability and growth. GSK still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the lead runs through profitability, while growth helps make the separation broader. The overall score gap is 18 points in favour of Orion Oyj.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GSK.L and ORNBV.HE share the same industry classification.

For a similarity-based comparison, see how GSK and Orion Oyj each position within their functional peer groups in AssetNext.

Peer-Relative Score
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh
vs
ORNBV.HE
Orion Oyj
83
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: GSK.L vs ORNBV.HE Profitability 46 100 Stability 69 71 Valuation 80 61 Growth 71 100 GSK.L ORNBV.HE
Gap Ranking
#1 Profitability +54
#2 Growth +29
#3 Valuation +19
#4 Stability +2
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and ORNBV.HE Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LORNBV.HE Relative valuation Structural strength

Orion Oyj occupies the cheaper side of the setup map, although GSK plc still holds the stronger structural profile.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both rank well on profitability, but Orion Oyj still holds a clear edge.
Growth
On growth, the same pattern holds: both rank well, but Orion Oyj still sits higher.
Profitability — Dominant Gap
GSK.L
46
ORNBV.HE
100
Gap+54in favour of ORNBV.HE

The profitability lead is mainly driven by a 28-point operating margin advantage.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for GSK, with a forward P/E that is 5.9 turns lower there.

What this means for the comparison

The lead is built on both profitability and growth — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the GSK.L vs ORNBV.HE comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-growth comparisons

Explore how GSK.L and ORNBV.HE each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.